



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01) C07K 16/30 (2006.01)
C07K 14/25 (2006.01) C12Q 1/6806 (2018.01)

(21) International Application Number:

PCT/US2022/073318

(22) International Filing Date:

30 June 2022 (30.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/218,198 02 July 2021 (02.07.2021) US

(71) Applicant: GIGAGEN, INC. [US/US]; One Tower Place,
Suite 750, South San Francisco, California 94080 (US).(72) Inventors: JOHNSON, David Scott; c/o GigaGen, Inc.,
One Tower Place, Suite 750, San Francisco, California
94080 (US). ADLER, Adam Shultz; c/o GigaGen, Inc.,
One Tower Place, Suite 750, San Francisco, California
94080 (US). MIZRAHI, Rena Aviva; c/o GigaGen, Inc.,

One Tower Place, Suite 750, San Francisco, California
94080 (US). LIM, Yoong Wearn; c/o GigaGen, Inc., One
Tower Place, Suite 750, San Francisco, California 94080
(US). ASENSIO, Michael; c/o GigaGen, Inc., One Tow-
er Place, Suite 750, San Francisco, California 94080 (US).
STONE, Erica Lyn; c/o GigaGen, Inc., One Tower Place,
Suite 750, San Francisco, California 94080 (US).

(74) Agent: BECKER, Daniel M. et al.; Fenwick & West LLP,
801 California Street, Mountain View, California 94041
(US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: Provided herein are antigen-binding proteins (ABPs) with binding specificity for CTLA-4 and compositions comprising such ABPs, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making CTLA-4 ABPs, and methods of using CTLA-4 ABPs, for example, for therapeutic purposes such as treating cancer, diagnostic purposes, and research purposes.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))